Materialise aMace

Most patient cases are Paprosky IIIA and IIIB types. aMace has been used in type II, dysplastic, and tumor cases as well. As the implant is custom-made for each patient, it can fit any defect. The medical indications can be summarized as follows:

• Non-inflammatory degenerative joint disease, including osteoarthritis and avascular necrosis
• Posttraumatic and rheumatoid arthritis
• Correction of functional deformity
• Revision procedures where other treatments or devices have failed
• Treatment in conjunction with tumor resection where bone stock is of poor quality or is inadequate for other reconstructive techniques as indicated by deficiencies of the acetabulum

Compared to standard implants with multiple components that need to be pieced intra-operatively, our one-piece solution eliminates the entire process of selection and assembly as well as the risks of intercomponent movements.

Contrary to standard implants, where the cost can increase over time depending on the clinical outcome, the cost is calculated upfront. The transparency and high-tech value of the experience make it a trustworthy, technical, and reliable solution. After comparing alternative solutions on the market, we've seen that preliminary data suggests that the aMace is a more cost-effective solution to treat complex acetabular defects.

The results of published follow-up data are very reassuring: a follow-up of two years, which is the typical timeframe for early failures, results in a 98% implant survival³ rate and 100% improved patient outcome⁴.

Read the clinical data summary

Currently, Materialise aMace is sold directly in Australia and Europe — Austria, Belgium, Finland, France, Germany, Ireland, the Netherlands, Norway, Sweden, Switzerland, and the United Kingdom. In Poland, our solution is sold through a distributor. It is not yet commercially available in Canada and the US.

It differs per country. They are dependent on legislation or hospitals' contracts with insurance companies, DRG systems, or special funds.

If you would like to know the specific reimbursement possibilities applicable to your country, please contact us at medical@materialise.com for more details.

You can contact your local sales representative in one of our offices or email medical@materialise.be. Our team will make sure to follow up on your request.

For your first case, we can work on a 3D analysis and planning report to give you an idea of the solutions we can offer. Fill out this contact form, and we’ll get in touch.

No, we do not provide unique printing services as we consider the planning and design an integral part of the quality assurance of our products.

The material properties of the porous structure match the mechanical properties of the bone, and the implant is made of a highly biocompatible material: Ti6AI4V ELI. Secondary fixation is improved as the solution is designed to allow bone ongrowth¹⁰. In addition, given the potentially large size of the defect-filling implants, porous structures allow total weight reduction of the implant.

Image data is uploaded directly to the patient case via Materialise SurgiCase. Image upload can be done by a surgeon, radiologist, or other staff. Please refer to the SurgiCase User Guide for ‘Image Upload’ instructions in the ‘Help’ menu in the SurgiCase platform for more information. If you don’t have an account, please contact your local sales representative or contact us at medical@materialise.com.

You can expect our 3D analysis and implant proposal within seven working days from the upload of acceptable images according to the Materialise hip scan protocol. The timing is dependent on your availability to provide feedback on the surgical plan. Once we receive approval on the final implant, the implant will be produced and delivered in 4 to 6 weeks.

It is advised to use the guides, implant, and models within six months of performing the CT scans on which they are based. If the patient’s anatomy has changed significantly since the time of the CT scan, the guides, models, and implant should not be used, even if the time period of six months has not expired.